Oncology
Bladder Transitional Cell Carcinoma
3
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
Bladder Transitional Cell Carcinoma is an early-stage landscape with 3 programs across 3 companies. The most active players are Amgen, Coherus Oncology, Inc., Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 11
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
3programs
Monoclonal antibody133%
Protein / enzyme133%
Gene therapy133%
Modality classified for 100% of 3 pipeline programs.
Analysis
Trial Status
1
clinical trials
Withdrawn1 · 100%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)